Galderma Laboratories can't soothe all of the irritations of the world, but it can help with itchy, spotty, and sensitive skin. The company is the North American operation of Swiss firm Galderma Pharma. As part of its business, Galderma Laboratories focuses exclusively on developing over-the-counter and prescription dermatology products. In addition to such consumer brands as Cetaphil, the company offers treatments for a variety of skin conditions. Areas of focus include remedies for acne, rosacea, atopic dermatitis (eczema), psoriasis, and melasma (darkening of the skin due to excessive melanin production). Galderma is owned by Switzerland's Nestlé,which bought out its joint venture partner in 2014.
Parent Galderma Pharma manufactures its products in Brazil, Canada, and France, with distribution networks that span more than 70 countries. It conducts research and development at facilities in France, Japan, Sweden, Switzerland, and the US. Galderma Laboratories' primary research center is located in Europe's largest high-technology park at Sophia-Antipolis in southeast France.
It is supported by clinical development centers in the US, Switzerland, and Japan.
The company's research involves using molecular, cellular, and in vivo bioassay systems to identify new therapies. The firm's scientists work in conjunction with dermatologists to help develop new skin treatments. Along with Cetaphil, Galderma Laboratories' lead products include Clobex to treat psoriasis, topical acne medication Differin, and rosacea therapies Metrogel and Oracea.
In addition with new product development, Galderma Pharma increases its size and scope through geographic expansion and, to a more limited extent, acquisitions to obtain new products and potential drug candidates. The company is also one of the world’s leading dermatology research and development players, investing some 19% of its annual revenues to access innovative technologies and to discover and develop new products.
To date, the company claims more than 5,000 patent applications and patents and 500 inventions.
In 2015 Galderma Labs launched Benzac Acne Solutions, its first-ever, over-the-counter acne regimen.
Growing its global skin health footprint, in 2014 Galderman Pharma gained full rights to distribute Restylane, Perlane, Emervel, Sculptra, and Dysport from Valeant Pharmaceuticals International.
Mergers and Acquisitions
In a deal that made Galderma Pharma the dermatology leader in Switzerland, the company in 2013 acquired Spirig Pharma A.G., which develops, produces, and markets dermatological products through a complementary holistic approach.
In 2012 it launched Cetaphil DermaControl products, formulated to address acne problems.
In 2011 Galderma Pharma acquired Swedish firm Q-Med, a competing maker of implanted dermatology products for aesthetic and therapeutic uses. The purchase brought in dermal wrinkle treatment Restylane as well as products to treat arthritis in the knees and incontinence. Galderma intends to make Q-Med into the base of its aesthetics division.
Galderma Laboratories is a regional unit of Galderma Pharma, formerly a joint venture (formed in 1981) between L'Oréal and Nestlé, but now wholly owned by Nestlé.